Bio-Techne Corp Stock 12‑Month Price Target Raised to $73.22, Implies 1% Upside
Bio-Techne Corp's stock has seen its average 12-month price target raised to $73.22, up from $70.9, based on estimates from 9 analysts. This new target implies a modest 1% potential upside from its Oct. 1 closing price. Despite the target increase, the consensus rating from 13 analysts remains a "Hold," with no Buy or Sell recommendations.
Form 4 Bio-Techne Corp For: 1 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Bio-Techne Corp related to activity on October 1st. It briefly mentions the company's stock symbol (TECH) and its current performance. The content is primarily a placeholder for financial news, indicating that a Form 4 was filed for Bio-Techne Corp.
Form 4 Bio-Techne Corp For: 1 October By Investing.com
This article reports on a Form 4 filing for Bio-Techne Corp (TECH) on October 1st, 2026. Form 4 filings disclose transactions by company insiders, and this article merely notes its existence. The content also includes various financial market data and popular news headlines from Investing.com.
Insider Activity Update: John L Higgins Executes Options Exercise, Resulting In $751K At Bio-Techne
John L Higgins, a Director at Bio-Techne (NASDAQ: TECH), recently exercised stock options for 15,940 shares, valued at $751,889. This transaction, filed with the SEC, involved an exercise price of $25.3 per share. The article also provides a detailed financial overview of Bio-Techne, highlighting its revenue growth, gross margin, EPS, debt management, and various valuation metrics.
Form 4 Bio-Techne Corp For: 1 October By Investing.com
This article announces the filing of a Form 4 for Bio-Techne Corp on October 1st, published by Investing.com. A Form 4 is a document required by the SEC to be filed by insiders of a company whenever there is a change in their ownership of the company's securities. The content is a brief notification surrounded by numerous navigation links and market data.
At $25.30 each, Bio-Techne (TECH) director John L. Higgins exercises 15,940 options.
Bio-Techne director John L. Higgins exercised 15,940 stock options at an exercise price of $25.30 on September 28, 2026, acquiring 15,940 common shares. He also had 5,562 shares withheld for tax liabilities at $72.51 per share. Higgins retains significant option holdings with various exercise prices and expiration dates through 2035.
Long term debt to total assets ratio of Bio-Techne Corporation – HAN:TE1
This article provides financial data for Bio-Techne Corporation (HAN:TE1) on TradingView, specifically focusing on its long-term debt to total assets ratio. It details the company's financial overview on the Hannover Stock Exchange. The content is presented within the TradingView platform context, indicating where users can find further financial information.
Book value per share of Bio-Techne Corporation – HAN:TE1
This article provides financial information for Bio-Techne Corporation (HAN:TE1), specifically focusing on its book value per share. The content is presented within the context of a financial data platform, showing market status and navigation to other financial metrics.
Bio-Techne Corporation Revenue Breakdown – HAN:TE1
Bio-Techne Corporation generated a total revenue of 1.06 billion EUR last year, with its Protein Sciences segment being the top performer, contributing 765.83 million EUR. The United States was the largest regional contributor to the company's revenue, accounting for 556.34 million EUR. This data highlights the key revenue drivers for Bio-Techne Corporation.
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne (NASDAQ: TECH) shareholders have approved the company's acquisition by Merck KGaA for $73 per share, valuing the company at $11.3 billion. Although the antitrust waiting period in the U.S. has expired, the deal awaits further regulatory approvals and is expected to close in late 2026 or early 2027. Shareholders, however, rejected the executive compensation package, signaling their disapproval of the terms, although this vote is advisory and not binding.
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne (TECH) shareholders have approved the acquisition of the company by Merck KGaA for $73 a share, valuing the business at approximately $11.3 billion. Simultaneously, shareholders rejected the executive compensation proposal tied to the deal, signaling their disapproval of the pay arrangements. The deal is expected to close in late 2026 or early 2027, pending remaining regulatory approvals outside the U.S., with the focus now shifting from price to timing for investors.
Qiagen N.V. (QGEN) Stock Price, News, Quote & History
This article provides a detailed financial overview of Qiagen N.V. (QGEN), including its current stock price, historical performance, key financial metrics, and analyst recommendations. It outlines the company's business in diagnostics and research, offering various sample to insight solutions globally. The report also highlights recent earnings, performance against benchmarks, and important valuation measures.
Robert V Baumgartner Exercises Options, Realizes $754K
Robert V Baumgartner, a Board Member at Bio-Techne (NASDAQ: TECH), exercised stock options for 15,940 shares, valued at $754,759. The transaction was disclosed in an SEC filing on September 24. Bio-Techne specializes in life sciences manufacturing, serving pharmaceutical, biotech, academic, and diagnostic markets, with its protein sciences segment being the largest revenue contributor.
Form 4 Bio-Techne Corp For: 25 September By Investing.com
This article reports on a Form 4 filing for Bio-Techne Corp on September 25, 2026. Form 4 documents insider trading activity, indicating that an insider at Bio-Techne Corp made a transaction on this date. The article is very brief and provides no additional details about the nature of the transaction or the insider involved.
Form 4 Bio-Techne Corp For: 25 September By Investing.com
The article reports on a Form 4 filing for Bio-Techne Corp (TECH) dated September 25, 2026. This brief piece, published by Investing.com, indicates the availability of insider trading information related to the company on the specified date. The core content is the announcement of this regulatory filing.
Form 4 Bio-Techne Corp For: 25 September By Investing.com
The article announces the filing of Form 4 for Bio-Techne Corp on September 25th. It is a very short piece of news from Investing.com, accompanied by market data and other popular articles.
Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes.
Bio-Techne director Robert V. Baumgartner exercised options for 15,940 common shares of TECH at an exercise price of $25.30. On the same date, 5,559 shares were delivered or withheld to cover the exercise price or tax liability, valued at $72.55 per share. The transaction report also details his remaining option tranches, with various exercise prices and expiration dates.
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, to enhance scientific discovery and customer collaboration in Europe. This flagship facility offers hands-on access to Bio-Techne's technologies and expertise, serving as a regional hub for researchers, biopharmaceutical companies, and clinical laboratories across the DACH and broader EMEA regions. The center aims to strengthen collaboration, training, and innovation within Europe's life sciences community, providing a space for evaluating integrated workflows and accelerating research from discovery to clinical application.
Form 8K Bio-Techne Corp For: 23 September By Investing.com
This article reports that Bio-Techne Corp filed a Form 8K on September 23, 2026. The brief announcement provides no further details but is accompanied by general stock market data and related news headlines.
Form 8K Bio-Techne Corp For: 23 September
This article reports on the filing of a Form 8K by Bio-Techne Corp on September 23. The filing is a standard regulatory announcement for significant events that shareholders should know about. No specific details about the content of the Form 8K are provided within this brief announcement.
Bio-Techne: Waiting Period Under Hart-Scott-Rodino Antitrust Act Expired >TECH
Bio-Techne announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its proposed acquisition of Exosome Diagnostics, Inc. has expired. This expiration allows Bio-Techne to proceed with the acquisition, which is expected to close on or about October 1, 2018.
Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle
Shareholders of Bio-Techne Corporation have approved the definitive merger agreement for Merck KGaA to acquire the company for approximately USD 11.3 billion. This all-cash deal, valued at USD 73.00 per share, represents Merck KGaA's largest acquisition since 2015 and an important strategic move under its new CEO. While the US antitrust waiting period has expired, regulatory reviews in other jurisdictions are ongoing, with closing expected in late 2026 or early 2027.
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation shareholders have approved the definitive agreement for Merck KGaA, Darmstadt, Germany to acquire the company. This marks a significant step towards completing the transaction, which is expected to close by late 2026 or early 2027, pending regulatory approvals. The acquisition aims to combine complementary life sciences organizations, offering substantial cash value to Bio-Techne shareholders and positioning the combined entity to support various life science workflows.
Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus
Bio-Techne (TECH) has opened a new Customer Experience Center in Düsseldorf, Germany, to allow European researchers to test its life science tools. This expansion comes as the company's shares have seen significant short-term gains, raising questions about whether its current valuation is sustainable or if most upside has already been realized. Despite recent momentum, the stock is considered about 3% overvalued with a fair value estimate of $70.73, and its long-term performance is down.
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne Corporation announced that its shareholders have approved the definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire Bio-Techne. This approval is a significant step towards combining the two life science organizations, aiming to provide substantial cash value to Bio-Techne shareholders and create a uniquely positioned company to support life science workflows. The transaction is expected to close by late 2026 or early 2027, pending customary closing conditions and regulatory approvals.
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, aimed at enhancing collaboration and scientific discovery within the European life sciences community. This flagship facility provides researchers with hands-on access to Bio-Techne's technologies and scientific expertise, fostering innovation across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. The center will also serve as a regional hub for training and thought leadership, strengthening Bio-Techne's engagement with academic institutions and biotech companies throughout Europe.
Bio-Techne opens customer experience center in Düsseldorf
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, to provide researchers and biopharmaceutical companies with access to its technologies. This facility will serve the DACH region and the broader EMEA regions, offering demonstrations and training in various life science fields. The center represents a significant investment by Bio-Techne to strengthen engagement with the scientific community and improve human health.
Bio-Techne opens customer experience center in Düsseldorf By Investing.com
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, to provide researchers, biopharmaceutical companies, and clinical laboratories with access to its technologies and workflows. This facility will serve the DACH region and the broader EMEA regions, offering demonstrations, training, and hands-on learning experiences in various scientific fields. The center aims to strengthen engagement with academic and biotech communities, reflecting a significant investment in the European scientific landscape.
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, to serve as a regional hub for researchers and organizations across Europe, the Middle East, and Africa. This flagship facility will provide hands-on access to Bio-Techne's technologies and scientific expertise, fostering collaboration, training, and innovation in the life sciences. The center aims to accelerate scientific discovery and improve patient outcomes by allowing visitors to explore integrated workflows and engage directly with Bio-Techne scientists.
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation has opened a new Customer Experience Center in Düsseldorf, Germany, to accelerate scientific discovery and collaboration in Europe. This flagship facility will provide hands-on access to Bio-Techne's technologies and expertise, serving as a regional hub for researchers and organizations in the DACH and broader EMEA regions. The center aims to strengthen collaboration, training, and innovation within Europe's life sciences community, offering integrated workflows and opportunities for hands-on experience across various scientific applications.
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne Corporation (NASDAQ: TECH) has opened a new Customer Experience Center in Düsseldorf, Germany, aimed at enhancing customer collaboration and accelerating scientific discovery in the DACH and broader EMEA regions. The facility provides hands-on access to Bio-Techne's technologies and scientific expertise, fostering innovation across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. This investment underscores Bio-Techne's commitment to supporting scientific excellence and bridging the gap between research and clinical application in Europe.
Bio-Techne Corporation (TECH) Options Chain - Yahoo Finance
The Yahoo Finance page for Bio-Techne Corporation (TECH) displays an options chain, but currently shows "Oops, something went wrong" and no available call or put options. It provides current stock performance data, showing TECH at $72.52 with no change, and includes related tickers in the biotechnology sector.
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
Bio-Techne (TECH) has seen its stock price rebound significantly over the past three months, though it's been flat recently. The company is currently valued as 4% overvalued based on a framework that considers long-term trends in therapies and diagnostics, driven by chronic and age-related diseases. Investors are encouraged to assess the underlying metrics and risks, such as prolonged biotech funding pressure or tougher tariffs, to determine future investment opportunities.
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit By Investing.com
Bio-Techne Corporation has released supplemental disclosures regarding its pending merger with Merck KGaA following a shareholder lawsuit and demand letters alleging misrepresentations in its proxy statement. The company denies the allegations but is providing additional information to avoid litigation and facilitate the shareholder vote. These disclosures include details on prior acquisition discussions, financial advisor engagement, and updated financial metrics.
Bio-Techne supplements proxy disclosures after shareholder suit, seeks shareholder vote on Sept. 23
Bio-Techne has supplemented its proxy statement following a shareholder lawsuit and demand letters related to the Merck KGaA acquisition. Despite allegations of disclosure deficiencies, which Bio-Techne deems meritless, the company voluntarily expanded its proxy disclosures to avoid delays and potential vote injunctions. A shareholder vote on the proposed merger is scheduled for September 23, 2026.
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit By Investing.com
Bio-Techne has released supplemental merger disclosures in response to a shareholder lawsuit alleging misrepresentations and omissions in its proxy statement regarding the pending merger with Merck KGaA. The company denies the allegations but is providing the additional information voluntarily to avoid litigation and ensure the shareholder vote on September 23 proceeds as scheduled. The disclosures provide details on prior acquisition discussions, financial advisor engagement, and updated financial metrics.
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit By Investing.com
Bio-Techne has released supplemental disclosures regarding its pending merger with Merck KGaA following a shareholder lawsuit and multiple demand letters alleging misrepresentations or omissions in its proxy statement. The lawsuit seeks to prevent the shareholder vote scheduled for September 23. Despite believing the allegations lack merit, Bio-Techne is voluntarily providing this additional information to mitigate litigation risks and ensure the vote proceeds.
Form 8K Bio-Techne Corp For: 14 September By Investing.com
This article reports on the filing of a Form 8K by Bio-Techne Corp on September 14, 2026. The brief announcement, published by Investing.com, indicates the routine disclosure of a significant event by the company as per SEC regulations. The content is concise, primarily serving as a notification of the filing.
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit
Bio-Techne Corporation has released supplemental disclosures regarding its pending merger with Merck KGaA following a shareholder lawsuit and demand letters alleging misrepresentations in its proxy statement. The company denies the allegations but is providing additional information to avoid litigation and proceed with the shareholder vote. The disclosures clarify details about prior acquisition discussions, financial advisor engagement, and executive employment talks.
Cleo Diagnostics Selects Bio-Techne’s US Laboratory for Pivotal Ovarian Cancer Test Validation
Cleo Diagnostics has partnered with Asuragen, Bio-Techne's CLIA-certified US laboratory, to validate its pre-surgical ovarian cancer test. This validation program involves over 1,300 samples and will provide clinical performance data for the company's planned FDA 510(k) submission in the first half of 2027. The collaboration strengthens Cleo's existing relationship with Bio-Techne, covering test kit manufacturing and the Ella diagnostic platform.
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Bio-Techne Corp (TECH), including its latest stock price, company description, and key financial fundamentals. It highlights recent news about the company, such as an investigation into shareholder deals and progress toward climate goals. The page also features trending news and polls related to other stocks and general financial topics.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
A new report forecasts the global research use recombinant protein market to grow from $1.11 billion in 2026 to $1.55 billion by 2031, driven by expanding therapeutic pipelines and increased preclinical research in advanced therapies. The market growth will be significantly influenced by the rising demand for human-derived proteins, especially cytokines and chemokines, across various research applications, with the US market expected to show the highest CAGR. Key players in this market include Thermo Fisher Scientific Inc., Bio-Techne, Merck KGaA, Danaher Corporation, and Revvity.
IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players
The global in vitro diagnostics (IVD) raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion by 2031, at a CAGR of 7.7%. This growth is driven by the rising prevalence of chronic and infectious diseases and increased demand for early and accurate diagnosis. Infectious disease testing and immunoassay technology are identified as the largest segments within the market.
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi). The company reduced market-based Scope 1 and 2 emissions by 49% year-over-year and now sources over half of its electricity from renewable sources. These achievements demonstrate Bio-Techne's commitment to responsible growth and reducing its environmental impact across operations and the value chain.
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation has announced significant progress towards its climate and sustainability goals, including the validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi). The company reduced its market-based Scope 1 and 2 emissions by 49% year-over-year in fiscal year 2026 and now sources more than half of its electricity from renewable sources. Bio-Techne aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 70% by fiscal year 2031 and ensure 81% of its suppliers have science-based targets by fiscal year 2030.
Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)
The article reviews the Q2 performance of several research tools and consumables stocks, highlighting Bruker (NASDAQ:BRKR) as having the weakest performance relative to analyst estimates and full-year guidance. In contrast, Avantor (NYSE:AVTR) achieved the best Q2 results with significant analyst estimate beats. Other companies like Waters Corporation (NYSE:WAT), Bio-Techne (NASDAQ:TECH), and Danaher (NYSE:DHR) also had varying Q2 outcomes.
Legal & General buys $19.51M stake in Bio-Techne
Legal & General Group Plc has acquired a new stake worth $19.51 million in Bio-Techne Corp, a biotechnology company providing tools and reagents for life sciences. This investment gives Legal & General a 0.18% stake in Bio-Techne, which recently reported strong earnings and revenue, increased its quarterly dividend significantly, and has seen institutional ownership rise to 98.95%. Analyst views are mixed despite the company's strong performance and share price near a 12-month high.
Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh
This page provides a financial overview of Bio-Techne Corporation's Unsponsored Brazilian Depository Receipts (T1CH34) on the B3 exchange. It highlights the company's revenue breakdown, with the United States being the largest contributor to its revenue in recent years. The page details segment performance by source and country.
Trading Systems Reacting to (TECH) Volatility
Bio-techne Corp (NASDAQ: TECH) is currently exhibiting neutral sentiment across all time horizons, suggesting a wait-and-see approach for investors. AI models have generated distinct trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis indicates compelling upside potential as no resistance levels remain above the current price.
Bio-Techne To Be Acquired by Merck KGaA
Merck KGaA announced on June 25, 2026, a proposed acquisition of Bio-Techne, a leader in proteins, immunoassays, and diagnostic reagents. This acquisition is anticipated to finalize by late 2026 or early 2027. Bio-Techne serves the academic, biopharmaceutical, and diagnostic markets with crucial products.
